Medindia

X

Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.

Saturday, January 10, 2009 General News J E 4
Advertisement
CHICAGO and PHOENIX, Jan. 9 Houlihan Smith & Co., Inc.acted as the exclusive advisor in arranging a non-control equity investmentinto Sottera, Inc. d/b/a NJOY, as announced by Charles Botchway, GroupManaging Director and Vice Chairman of Houlihan Smith & Company, Inc. Thetransaction was led by Houlihan Smith Managing Director Reginald McGaugh.Terms were not disclosed.

"We appreciate the process management and financial advisory servicesprovided by Reginald McGaugh and his team at Houlihan Smith & Company, Inc.related to this equity investment," said Jack Leadbeater, CEO of Sottera. "Welook forward to continuing our capital-raising process with Mr. McGaugh andhis team as we continue our international growth."

"This investment represents a significant opportunity for NJOY to achievegrowth initiatives related to its revolutionary product," said McGaugh, whoworked directly with NJOY to establish the equity investment. "The facilitywill be used to support the continued growth of NJOY based on recently signeddistribution agreements in North America, South America, and Asia."

Based in Scottsdale, Arizona, Sottera has filed for patents to manufactureand distribute groundbreaking products and technology represented by thetrademarked brand NJOY (http://www.njoy.com). The name Sottera is derivedfrom Soteria, the Greek god of preservation, redemption and salvation. Thesethree words are the essence of the NJOY brand and products, which give tobaccousers the opportunity to continue smoking with greater freedom, lower cost andmore social acceptance. NJOY is currently being sold in all 50 states and inmore than 25 foreign countries. NJOY is available online athttp://www.njoy.com for shipment around the globe, and is also available onaffiliated websites and at retail locations across the U.S.

Miri Pharma, Inc. is a division of Canderm Pharma, Inc. Canderm Pharma,Inc. develops and sells cosmeceuticals, over-the-counter (OTC) skin careproducts, and dermatological items. Its product line includes ArtteSense,Betacaine, Cliniderm, Lipsorex, NeoStrata, Rosacure, and Ultraquin, as well asCondyline Topical Solution, Dermagran II, Epi-Derm, and UltraMOP. The firmalso sells Ayria, a skin care line sold exclusively through dermatologists,and distributes Radiesse, produced by BioForm Medical, a trendy injectablefiller alternative to facelifts.

Houlihan Smith & Company, Inc. ("Houlihan") is a specialized investmentbanking firm that provides advisory, financing, and valuation services topublic and private businesses. Houlihan is a registered broker-dealer andFINRA/SIPC Member.

Houlihan understands the time sensitivity of corporate finance, andresponds quickly and tenaciously to opportunities. The Houlihan approachcreates corporate finance transactions in which business owners and investorsmutually benefit. We have the knowledge, experience and relationships to matchbuyers and sellers, as well as to match the appropriate financing andcapitalization structure to each unique client situation. The Houlihan nameis synonymous with professional financial expertise. We providecost-effective fairness and solvency opinions, as well as valuations for taxand financial reporting, to some of the largest NYSE/NASDAQ companies, as wellas small, privately held businesses. (http://www.houlihansmith.com)Contact: Rebecca Carriere 312.499.5903 rcarriere@houlihan.com

SOURCE Houlihan Smith & Co., Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Human Genome Sciences Invites Investors to Listen ...
S
Report Finds That Raids Are Not an Effective Tool ...